Enveric Biosciences, Inc. (ENVB): Nasdaq/NYSE listing notice — Enveric Biosciences gets Nasdaq extension to meet $2.5M equity requirement by May 20, 2024

Enveric Biosciences, Inc.

Nasdaq granted extension to May 20, 2024 to meet minimum $2,500,000 stockholders' equity requirement.
If compliance not evidenced by May 20, 2024, Nasdaq may issue delisting notice.
Additional compliance deadline: filing of periodic report for June 30, 2024; failure may lead to delisting.
Company states it plans to regain compliance with the equity requirement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Enveric Biosciences, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

February 6, 2024, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Enveric Biosciences, Inc. (the “Company”) that based on the Staff’s review of materials submitted by the Company to Nasdaq, the Staff determined to grant the Company an extension to regain compliance with the minimum stockholders’ equity requirement of at least $2,500,000 as set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”). The deficiency with respect to the Company’s compliance with the S

View on SEC.gov

Browse all listing & compliance notices →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-005561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.